close 74% rachunków inwestorów detalicznych odnotowuje straty w wyniku handlu kontraktami CFD u niniejszego dostawcy. Inwestowanie wiąże się z ryzykiem i nie jest odpowiednie dla wszystkich inwestorów. Kontrakty CFD są złożonymi instrumentami i wiążą się z dużym ryzykiem szybkiej utraty środków pieniężnych z powodu dźwigni finansowej. 74% rachunków inwestorów detalicznych odnotowuje straty w wyniku handlu kontraktami CFD u niniejszego dostawcy. Upewnij się, czy rozumiesz, jak działają kontrakty CFD, i czy możesz pozwolić sobie na wysokie ryzyko utraty pieniędzy.
Change languagePolski
Pulpit

LLY

1,011.27

-2.12%↓

JNJ

243.2

-0.52%↓

ABBV

223.56

-2.05%↓

NVS

165.44

-1.33%↓

MRK

119.45

-2.56%↓

LLY

1,011.27

-2.12%↓

JNJ

243.2

-0.52%↓

ABBV

223.56

-2.05%↓

NVS

165.44

-1.33%↓

MRK

119.45

-2.56%↓

LLY

1,011.27

-2.12%↓

JNJ

243.2

-0.52%↓

ABBV

223.56

-2.05%↓

NVS

165.44

-1.33%↓

MRK

119.45

-2.56%↓

LLY

1,011.27

-2.12%↓

JNJ

243.2

-0.52%↓

ABBV

223.56

-2.05%↓

NVS

165.44

-1.33%↓

MRK

119.45

-2.56%↓

LLY

1,011.27

-2.12%↓

JNJ

243.2

-0.52%↓

ABBV

223.56

-2.05%↓

NVS

165.44

-1.33%↓

MRK

119.45

-2.56%↓

Strona główna・Stock List・Karyopharm Therapeutics Inc
Search

Karyopharm Therapeutics Inc

Open

SectorHealthcare

9.24 -8.33

Strong Buy

Price update 26 lut 2026, 16:20 UTC

BuySell

Overview

Share price change

24h

Current

Min

9.11

Max

10.12

Key metrics

By Trading Economics

Income

-69M

-102M

Sales

-10M

34M

EPS

-2.227

Profit margin

-299.886

Employees

228

EBITDA

4.7M

-18M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+65.54% upside

Market Stats

By TradingEconomics

Market Cap

27M

184M

Previous open

17.57

Previous close

9.24

News Sentiment

By Acuity

50%

50%

167 / 351 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Bullish Evidence

5.9501 / 7.66 Support & Resistance

Karyopharm Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

25 lut 2026, 23:25 UTC

Hot Stocks

Stocks to Watch: C3.ai, Salesforce, Pure Storage, Zoom

DJ

Read

25 lut 2026, 23:15 UTC

Earnings

Salesforce Sees Stable Growth; CEO Dismisses Talk of AI-Fueled 'SaaS-Pocalypse' -- 2nd Update

DJ

Read

25 lut 2026, 23:54 UTC

Market Talk

Gold Steady Ahead of U.S.-Iran Talks -- Market Talk

DJ

Read

25 lut 2026, 23:47 UTC

Earnings

Ferrovial 4Q Net EUR197M >FER.MC

DJ

Read

25 lut 2026, 23:45 UTC

Earnings

Ferrovial 4Q Rev EUR2.72B >FER.MC

DJ

Read

25 lut 2026, 23:42 UTC

Earnings

Nvidia Beats Back Bubble Fears With Record $68 Billion Sales in Fourth Quarter -- 4th Update

DJ

Read

25 lut 2026, 23:38 UTC

Market Talk

Nikkei May Rise, Tracking Wall Street's Gains -- Market Talk

DJ

Read

25 lut 2026, 23:25 UTC

Earnings

Trip.com: Company's Business Operations Remain Normal >TCOM

DJ

Read

25 lut 2026, 23:25 UTC

Earnings

Trip.com Gives Update on Investigation by China's State Administration for Market Regulation >TCOM

DJ

Read

25 lut 2026, 23:25 UTC

Earnings

Trip.com: Cannot Predict Status or Results of Investigation, Will Provide Updates on Conclusion >TCOM

DJ

Read

25 lut 2026, 23:25 UTC

Earnings

Trip.com Increase in FY Profit Primarily Due to Gain From Investments >TCOM

DJ

Read

25 lut 2026, 23:25 UTC

Earnings

Trip.com Will Continue to Communicate With SAMR on Compliance With Regulatory Requirements >TCOM

DJ

Read

25 lut 2026, 23:25 UTC

Earnings

Trip.com: SAMR Investigation Related to China's Anti-monopoly Law >TCOM

DJ

Read

25 lut 2026, 23:25 UTC

Earnings

Trip.com: Investigation Ongoing, Company Is Cooperating With SAMR >TCOM

DJ

Read

25 lut 2026, 23:25 UTC

Earnings

Trip.com Co-founders Min Fan, Qi Ji Resign From Positions >TCOM

DJ

Read

25 lut 2026, 23:25 UTC

Earnings

Trip.com: Fan Resigned as Director and President; Ji Resigned as a Director >TCOM

DJ

Read

25 lut 2026, 23:25 UTC

Earnings

Trip.com FY Rev CNY62.4B, Up 17% >TCOM

DJ

Read

25 lut 2026, 23:25 UTC

Earnings

Trip.com FY Net CNY33.3B Vs. Net CNY17.1B >TCOM

DJ

Read

25 lut 2026, 23:25 UTC

Earnings

Trip.com FY EPS CNY47.67 >TCOM

DJ

Read

25 lut 2026, 23:06 UTC

Earnings

Correction to Nvidia Fourth Quarter Results Article -- WSJ

DJ

Read

25 lut 2026, 23:01 UTC

Earnings

Nvidia Beats Back Bubble Fears With Record $68 Billion Sales in Fourth Quarter -- 3rd Update

DJ

Read

25 lut 2026, 23:00 UTC

Market Talk
Earnings

Global Equities Roundup: Market Talk

DJ

Read

25 lut 2026, 23:00 UTC

Market Talk
Earnings

Nvidia: Chinese Competitors Pose Risk to U.S. Dominance in AI -- Market Talk

DJ

Read

25 lut 2026, 22:56 UTC

Market Talk
Earnings

Nvidia CEO Says Customers Can't Grow Revenue Without Compute -- Market Talk

DJ

Read

25 lut 2026, 22:43 UTC

Earnings
Acquisitions, Mergers, Takeovers

Paramount Streaming Revenue Rises, but TV Segment Faces Headwinds -- WSJ

DJ

Read

25 lut 2026, 22:40 UTC

Market Talk
Earnings

Nvidia Says Agentic AI Has Reached Inflection Point -- Market Talk

DJ

Read

25 lut 2026, 22:40 UTC

Earnings

Karoon Energy Says Search for New CFO Well Advanced

DJ

Read

25 lut 2026, 22:39 UTC

Earnings

Karoon Energy Says CFO Ray Church to Leave Company

DJ

Read

25 lut 2026, 22:39 UTC

Earnings

Karoon Energy Says On-Market Share Buyback Program Ongoing at Moderated Level

DJ

Read

25 lut 2026, 22:38 UTC

Earnings

Karoon Energy Says Guidance for 2026 Key Metrics Unchanged

DJ

Read

Peer Comparison

Price change

Karyopharm Therapeutics Inc Forecast

Price Target

By TipRanks

65.54% upside

12 Months Forecast

Average 16.67 USD  65.54%

High 23 USD

Low 12 USD

Based on 4 Wall Street analysts offering 12 month price targets forKaryopharm Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

4 ratings

4

Buy

0

Hold

0

Sell

Based on 4 analysts giving stock ratings to Karyopharm Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

5.9501 / 7.66Support & Resistance

Short Term

Bullish Evidence

Recent bullish events outweigh bearish events.

Intermediate Term

Strong Bearish Evidence

All events are bearish.

Long Term

No Evidence

There are no events.

Sentiment

By Acuity

167 / 351 Ranking in Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

Other stocks from the sector

LLY

Eli Lilly and Co.

1,011.27

↓-2.12%

JNJ

Johnson and Johnson

243.2

↓-0.52%

ABBV

AbbVie Inc

223.56

↓-2.05%

NVS

Novartis AG

165.44

↓-1.33%

MRK

Merck & Co Inc.

119.45

↓-2.56%
help-icon Live chat